Hormonal
Subcutaneous semaglutide (0.5 mg and 1.0 mg) significantly reduces HbA1c and body weight in Type 2 Diabetes patients compared to placebo and other antidiabetic agents.
If you have Type 2 Diabetes, once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) is a highly effective treatment for lowering blood sugar (HbA1c) and reducing body weight. It works better than many other standard diabetes medications and placebo. Be prepared for potential nausea or diarrhea, which are common but often mild and decrease over time.
For efficacy, compared with placebo, semaglutide exhibited beneficial effects on glycosylated hemoglobin A1c (HbA1c) control [MD -0.97%, 95% CI (-1.33, -0.62), I2 = 91%; MD -1.36%, 95% CI (-1.59, -1.13), I2 = 84%, semaglutide 0.5 and 1.0 mg, respectively], body weight reduction, blood pressure control.
Why this rating
Meta-analysis of 17 RCTs with 14,940 patients.
Source
Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis
Shanshan Hu et al. · Diabetology & Metabolic Syndrome · 2023
DOI 10.1186/s13098-023-01195-7
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →